RUFFER INVST PART RED PRE by Ruffer Investment Company Ltd. Stock (OTC: RUFIF)

Latest news for RUFFER INVST PART RED PRE by Ruffer Investment Company Ltd. (OTC:RUFIF) Stock

RUFFER INVST PART RED PRE by Ruffer Investment Company Ltd.

TD Synnex's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) short percent of float has risen 24.38% since its last report. The company recently reported that it has 2.00 million shares sold short, which is 3.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>TD Synnex Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734723921_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for TD Synnex has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing TD Synnex's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, TD Synnex's peer group average for short interest as a percentage of float is 4.75%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into TD Synnex's Recent Short Interest

GoPro's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPRO#NYSE">GPRO</a>) short percent of float has risen 24.92% since its last report. The company recently reported that it has 5.07 million shares sold short, which is 4.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.47 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>GoPro Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734723917_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for GoPro has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing GoPro's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, GoPro's peer group average for short interest as a percentage of float is 4.82%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

GPRO

Peering Into GoPro's Recent Short Interest

Novavax's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NYSE">NVAX</a>) short percent of float has fallen 4.18% since its last report. The company recently reported that it has 39.78 million shares sold short, which is 30.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novavax Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734723911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novavax has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Novavax's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novavax's peer group average for short interest as a percentage of float is 14.45%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

NVAX

Peering Into Novavax's Recent Short Interest

WIIM

AFRM

Affirm Holdings shares are trading higher after JMP Securities upgraded the stock from Market Perform to Market Outperform while maintaining its price target at $78.

<a href="https://www.usitc.gov/press_room/news_release/2024/er1220_66270.htm" title="https://www.usitc.gov/press_room/news_release/2024/er1220_66270.htm">https://www.usitc.gov/press_room/news_release/2024/er1220_66270.htm</a>

News

DELL

USITC Institutes Section 337 Investigation Of Certain Wireless Communication Devices And Components Thereof; Probe Certain Smart TVs Made By Dell, HP, Lenovo After Request By International Semiconductor Group Co

On Friday,&nbsp;Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) released headline results from the REDEFINE 1 Phase 3 trial in the&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">global REDEFINE program</a>.
When evaluating the effects of treatment if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone.
In November, Novo Nordisk said its hybrid drug, CagriSema, aims to reduce weight by 25% without&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41706292/as-race-to-best-miracle-obesity-drug-heats-up-ozempic-maker-novo-nordisk-tests-new-hybrid-drug-th" rel="noreferrer noopener">added side effects</a>.
William Blair points out that Novo Nordisk didn&#8217;t provide detailed tolerability data in its press release, making it hard to compare their treatment with Eli Lilly&#8217;s Zepbound directly. However, only 57% of patients could increase their dose to the highest level with CagriSema, compared to 83% with cagrilintide and 70% with Wegovy, suggesting that CagriSema may have a tougher tolerability profile.
The analyst writes the tolerability issue is a key reason why investors are concerned about the REDEFINE 1 trial. The analyst <a href="https://www.benzinga.com/quote/amgn/analyst-ratings" target="_blank" rel="noreferrer noopener">rates the shares Outperform</a>.
The results from CagriSema are also beneficial for Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), which recently showed that its GLP-1R agonist/GIPR antagonist, MariTide, leads to effective <a target="_blank" href="https://www.benzinga.com/24/11/42189129/amgen-reveals-data-from-closely-watched-monthly-obesity-drug-with-weight-loss-of-up-to-20-at-one-year-and-no-plateau" rel="noreferrer noopener">weight loss in Phase 2 trials.</a>
MariTide&#8217;s weight loss of about 20% after 52 weeks (or 18% at the 420 mg dose) is similar to or slightly below the weight loss seen with other GLP-1 therapies, such as CagriSema and Zepbound.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41950871/amgen-defends-its-investigational-monthly-weight-loss-injection-after-analyst-cites-maritides-impact-on-bone-density" rel="noreferrer noopener">Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide&#8217;s Impact on Bone Density</a>
The analyst writes that MariTide&#8217;s advantage could lie in its less frequent monthly dosing, which may stand out in the obesity market.
Additionally, the way MariTide is dosed appears to reduce gastrointestinal side effects with the first dose, suggesting it may have a more tolerable long-term profile and improve patient adherence.
Price Action: AMGN stock is up 1.58% at $265.33 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42621868/nvidia-secures-eu-approval-for-runai-deal-us-probes-china-export-breach" target="_blank" rel="noreferrer noopener">Nvidia Secures EU Approval For Run:ai Deal, US Probes China Export Breach</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Biotech

Equities

Large Cap

Health Care

Analyst Ratings

Movers

General

AMGN

What's Going On With Amgen Stock On Friday?

Legal

NPSCY

Nippon Steel, U.S. Steel Allege White House Has Had 'Impermissible Influence' Over CFIUS Review Of Proposed Tie-Up-Letter; White House Denies Allegations Of Undue Influence; Nippon Steel, U.S. Steel Vow To Challenge An Expected Block Of The Deal In U.S. Court As A Violation Of Due Process And Authority Of The President Under CFIUS Rules-Letter

Value stocks are having a rough go in 2024, at least compared to broader stock indexes.
The benchmark S&amp;P Value Index is up 10.46% on a year-to-date basis. That's well below the S&amp;P 500, which has generated 23.8% returns over the same time period. The index is also well below the year-to-date performance of the S&amp;P Growth Index, which stands at 35.11% as of December 20.
Yet as the calendar flips to 2025, value stocks seem to be in a decent position.
Here&#8217;s three reasons why value stocks may be a good bet for 2025.
"Inflation is moderating, and the economy seems to be steadying," says Jason Hishmeh, co-founder at Varyence, a technology firm that works with startup companies to grow their business. "That's great news for sectors like manufacturing, financials, and energy, which tend to perform well in this environment. Companies with strong fundamentals—low price-to-earnings ratios and steady earnings growth—look particularly attractive."
Other market experts say Main Street investors need to get a good grip on what value stocks really represent.
"Value stocks are a group of underappreciated and ignored stocks that are worth more than their fundamentals would suggest," says Stephen Callahan, trading behavior analyst at Firstrade. "This is a market driven by momentum. As a value investor, valuations are never a reason to own something. Fundamentals are the reason why you own something. We need to match those two things up." What's more, not all cheap stocks are value stocks.
"Some stocks are cheap for quantifiable reasons, such as poor earnings," Callahan says. "Value stocks are good companies at low prices. They are financially stable, have high-profit margins, low debt-to-income ratio, strong earnings, and while not mandatory, a good sign is that they pay dividends."
Value stocks have several trends pointing upward heading into a new year. Market experts point to these largest 2025 impactors.
<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-holiday-24/?t=be16bespmirebz36&amp;utm_source=WebRD-1219">[65% Off Benzinga Edge – Sale Ends December 31!]</a>
Back in business under Trump. President-elect Donald Trump said he'd prioritize a business-friendly agenda in his campaign stump speeches, which would be good news for value stocks.
"Trump spoke frequently about reducing the government deficit, lowering energy costs through increased domestic drilling, and implementing potentially looser regulations," says Ronen Cojocaru, CEO at San Francisco-based 8081.io, a fintech company that simplifies and automates digital asset trading. "Additionally, the prospect of corporate-friendly tax reforms could enhance profitability, making value stocks more attractive to investors."
Key expectations coming from the Trump camp include reduced regulations in sectors such as energy, financials, crypto, and industrials, which could lower compliance costs and increase profitability.
"Additionally, corporate-friendly tax reforms may enhance earnings, while a focus on domestic production and energy independence could create new opportunities for growth in the energy and manufacturing sectors," Cojocaru says. "But we should all look carefully at how Trump administration tariffs will take place, which can play a significant role in that space."
Large-cap value stocks to shine. In early December, BofA analysts projected the U.S. gross domestic product would rise by 2.4%, well ahead of other analyst projections that landed in the 2.0% range. Economists say that any GDP above 2% is good news for well-run, long-established companies that turn a profit.
So-called "GDP-sensitive" companies should benefit from a growing U.S. economy. &#8220;We see more opportunities in stocks than the index,&#8221; notes BofA head of U.S. equity and quantitative strategy Savita Subramanian in a recent research note, which pegged the S&amp;P 500 at a 6,666 target price for 2025. &#8220;In particular, we like companies with healthy cash return prospects and a tether to the US economy: large-cap value stocks.&#8221;
Cojocaru says large-cap value stocks are well-positioned to perform strongly in 2025, especially if the trends highlighted by BofA analysts continue to shape the market.
"Companies in this sector demonstrated remarkable resilience in 2024, navigating a high-inflation environment by adopting strict cost controls, improving operational efficiency, and managing capital strategically," he notes. "These actions now yield significant benefits as inflation moderates and interest rates show signs of stabilizing or potentially declining."
An upward trending economy. With analysts calling for a healthy US economy, a strong labor market, moderating inflation, and the resulting potential for further interest rate cuts, value stocks should rise accordingly.
"The economy is looking pretty solid right now, with strong jobs, inflation starting to settle, and maybe even some interest rate cuts on the horizon,"&nbsp; says Nick Scibilia, CEO of Orbit, a social media platform geared toward younger investors.&nbsp;
That scenario represents "awesome news" for value stocks, Scibilia notes. "People are spending more, businesses are booming, and that means more cash for those established companies," he says. "Plus, if interest rates drop, those steady dividend-paying value stocks will look even better."
Watch out for risks. Even with a generally rosy outlook on the sector, value investors should know various possible risks.
"Firstly, if inflation persists and interest rates continue to increase, value stocks could underperform," Scibilia says. "Secondly, a recession is still possible, and value stocks are not immune to economic downturns. Lastly, geopolitical uncertainty and global events could disrupt market conditions and negatively impact value stocks."
Still, Scibilia sees several sectors looking pretty hot right now.
"Energy has been a bit wild lately with prices bouncing around, but things are looking good long term," he notes. "Also, when the economy is humming, industrials are in high demand. Think infrastructure, manufacturing, transportation &#8211; they&#8217;re all key players in keeping things moving."
Additionally, robust economic fundamentals should help stocks across the board next year.
&#8220;A stronger economy is good for all solid companies, even ones that aren't considered value stocks right now," says Paul Gabrail, founder and host of the Everything Money YouTube channel. "The goal is to increase revenue and profit; over time, the stock price and value of the company will converge.&#8221;
Find the market's fastest-moving stocks and access real-time alerts, expert trade setups, and insider stock picks with Benzinga Edge. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-holiday-24/?t=be16bespmirebz36&amp;utm_source=WebRD-1219">Click here to take advantage of our End-of-Year Sale which ends December 31!</a>
Image via Pixabay

Opinion

3 Reasons to Buy Value Stocks Before January 1

RDDT

Reddit shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and a $210 price target.

Financial giants have made a conspicuous bearish move on Super Micro Computer. Our analysis of options history for Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) revealed 28 unusual trades.
Delving into the details, we found 39% of traders were bullish, while 46% showed bearish tendencies. Out of all the trades we spotted, 15 were puts, with a value of $865,180, and 13 were calls, valued at $493,490.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $7.0 to $90.0 for Super Micro Computer over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Super Micro Computer's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Super Micro Computer's significant trades, within a strike price range of $7.0 to $90.0, over the past month.
<h3>Super Micro Computer 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734723033_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$19.05</td>
<td>$18.9</td>
<td>$18.98</td>
<td>$50.00</td>
<td>$189.8K</td>
<td>3.9K</td>
<td align="right">150</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/24/25</td>
<td>$19.5</td>
<td>$18.7</td>
<td>$19.4</td>
<td>$50.00</td>
<td>$96.9K</td>
<td>38</td>
<td align="right">50</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$58.7</td>
<td>$57.9</td>
<td>$58.6</td>
<td>$90.00</td>
<td>$93.7K</td>
<td>686</td>
<td align="right">16</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$6.7</td>
<td>$6.55</td>
<td>$6.65</td>
<td>$33.00</td>
<td>$66.5K</td>
<td>5.9K</td>
<td align="right">203</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$6.35</td>
<td>$6.1</td>
<td>$6.27</td>
<td>$32.00</td>
<td>$62.7K</td>
<td>890</td>
<td align="right">252</td>
</tr>
</tbody>
</table>

<h3>About Super Micro Computer</h3>
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data center, Big Data, high-performance computing, and "Internet of Things" embedded markets. Its solutions include server, storage, blade and workstations to full racks, networking devices, and server management software. The firm follows a modular architectural approach, which provides flexibility to deliver customized solutions. The Company operates in one operating segment that develops and provides high-performance server solutions based upon an innovative, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
Following our analysis of the options activities associated with Super Micro Computer, we pivot to a closer look at the company's own performance.
<h3>Where Is Super Micro Computer Standing Right Now?</h3>
<ul>
<li>With a volume of 31,110,491, the price of SMCI is up 3.09% at $32.2. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 11 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Super Micro Computer with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

SMCI

What the Options Market Tells Us About Super Micro Computer

Deep-pocketed investors have adopted a bearish approach towards Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in QCOM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 19 extraordinary options activities for Qualcomm. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 26% leaning bullish and 42% bearish. Among these notable options, 7 are puts, totaling $664,115, and 12 are calls, amounting to $1,189,524.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $140.0 to $180.0 for Qualcomm during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Qualcomm's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Qualcomm's substantial trades, within a strike price spectrum from $140.0 to $180.0 over the preceding 30 days.
<h3>Qualcomm Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734723028_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$23.75</td>
<td>$23.3</td>
<td>$23.75</td>
<td>$140.00</td>
<td>$474.6K</td>
<td>142</td>
<td align="right">200</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$2.29</td>
<td>$2.13</td>
<td>$2.14</td>
<td>$180.00</td>
<td>$242.0K</td>
<td>2.8K</td>
<td align="right">20</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$15.05</td>
<td>$14.5</td>
<td>$14.5</td>
<td>$165.00</td>
<td>$211.7K</td>
<td>1.2K</td>
<td align="right">26</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.9</td>
<td>$5.7</td>
<td>$5.75</td>
<td>$150.00</td>
<td>$129.3K</td>
<td>8.2K</td>
<td align="right">390</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$18.15</td>
<td>$17.85</td>
<td>$18.01</td>
<td>$170.00</td>
<td>$90.0K</td>
<td>8.6K</td>
<td align="right">346</td>
</tr>
</tbody>
</table>

<h3>About Qualcomm</h3>
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.
<h3>Current Position of Qualcomm</h3>
<ul>
<li>With a volume of 4,767,794, the price of QCOM is up 1.8% at $153.1. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 40 days.</li>
</ul>
<h3>What The Experts Say On Qualcomm</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $180.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Melius Research has revised its rating downward to Hold, adjusting the price target to $180. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Qualcomm with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

QCOM

Spotlight on Qualcomm: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 35 extraordinary options activities for Advanced Micro Devices. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 65% leaning bullish and 14% bearish. Among these notable options, 16 are puts, totaling $1,369,153, and 19 are calls, amounting to $2,358,178.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $230.0 for Advanced Micro Devices over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Advanced Micro Devices's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Advanced Micro Devices's whale trades within a strike price range from $85.0 to $230.0 in the last 30 days. 
<h3>Advanced Micro Devices Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734723023_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$37.25</td>
<td>$37.15</td>
<td>$37.15</td>
<td>$100.00</td>
<td>$1.4M</td>
<td>8.1K</td>
<td>3.1K</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$71.75</td>
<td>$71.6</td>
<td>$71.6</td>
<td>$190.00</td>
<td>$400.9K</td>
<td>1.7K</td>
<td>56</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$21.75</td>
<td>$21.55</td>
<td>$21.61</td>
<td>$140.00</td>
<td>$252.8K</td>
<td>3.7K</td>
<td>1</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$17.55</td>
<td>$17.5</td>
<td>$17.55</td>
<td>$130.00</td>
<td>$93.0K</td>
<td>15.2K</td>
<td>302</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$22.15</td>
<td>$21.8</td>
<td>$22.0</td>
<td>$150.00</td>
<td>$88.0K</td>
<td>3.5K</td>
<td>44</td>
</tr>
</tbody>
</table>

<h3>About Advanced Micro Devices</h3>
Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications. AMD's traditional strength was in central processing units and graphics processing units used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array leader Xilinx to diversify its business and augment its opportunities in key end markets such as data center and automotive.
After a thorough review of the options trading surrounding Advanced Micro Devices, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Advanced Micro Devices</h3>
<ul>
<li>Trading volume stands at 29,364,681, with AMD's price up by 0.98%, positioned at $120.04.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 39 days.</li>
</ul>
<h3>Professional Analyst Ratings for Advanced Micro Devices</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $164.33333333333334.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Advanced Micro Devices, maintaining a target price of $158. 
&#x2A; An analyst from B of A Securities has revised its rating downward to Neutral, adjusting the price target to $155. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Advanced Micro Devices, targeting a price of $180. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Advanced Micro Devices, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on AMD Options

QUBT

Quantum Computing shares are trading higher. The company announced a $2.9 million share offering of 8.96 million shares for resale by the selling stockholder.

Billionaire Stanley Druckenmiller, a former confidant of George Soros and the founder of Duquesne Capital, built his career off making <a href="https://www.benzinga.com/general/24/03/37598371/stanley-druckenmillers-secret-sauce-the-two-stocks-dominating-a-quarter-of-his-three-billion-dollar">large, measured bets</a>. His latest large wager has paid off.
The famed investor has steadily increased his stake in Natera Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a clinical genetic testing company, since the third quarter of 2022, according to quarterly 13F filings. Druckenmiller owned 414,955 shares in 2022&#8217;s third quarter, 893,030 shares in 2023 and 3,566,850 shares in 2024.
Druckenmiller&#8217;s position now exceeds $575 million, nearly 3% of the Austin, Texas-based company&#8217;s market capitalization and 15% of Duquesne Capital&#8217;s portfolio.
Since Duquesne Capital revealed its stake in a 13F filing, its stock has traded up 268%. Meanwhile, the healthcare industry as a whole, as measured by the iShares US Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>), has risen a touch over 16%. Thus, Druckenmiller&#8217;s gamble has outperformed its sector by over 250%.
Also Read: <a href="https://www.benzinga.com/markets/equities/24/12/42624528/government-shutdown-threat-stocks-wobble-holiday-travel-and-paychecks-could-face-delays-what-you-need-to-know">Government Shutdown Threat: Holiday Travel, Paychecks Could Face Delays If No Deal Reached</a>
Natera specializes in genetic testing and diagnostics to improve healthcare outcomes. The company develops and markets tests that analyze DNA to provide insights into hereditary conditions, reproductive health, organ transplant health, and oncology. 
Natera's flagship products include non-invasive prenatal tests (NIPTs) like Panorama, which screens for chromosomal abnormalities in a fetus, and Horizon, a carrier screening test for hereditary conditions.
In recent years, Natera has expanded its focus to oncology and organ transplant monitoring. In oncology, the company's Signatera test detects minimal residual disease (MRD) in cancer patients, helping to guide treatment decisions and monitor for recurrence with precision.
In the transplant space, the Prospera test assesses organ health by measuring donor-derived cell-free DNA, providing early indications of transplant rejection.
The company has beaten earnings and revenue expectations over the past four quarters. Revenue has increased from $625 million in 2021 to $1.5 billion over the past twelve months, while margins have also expanded. The company has posted a positive operating cash flow since March.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42623343/exclusive-weight-loss-market-experts-scoop-up-novo-nordisk-stock-after-worst-drop-since-2002-following-drug-trial-miss">EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Hedge Funds

iShares Trust Dow Jones US Healthcare Sector Index Fund

NTRA

Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%

Rumors

Watching Nano Nuclear Energy; Shares See A Pop To The Upside As Traders Circulate Popular Stock Trader X Account Suggesting They Have Taken A Long Position On The Stock

Macro Economic Events

Politics

Economics

U.S. House Speaker Johnson Says We Have A Unified Agreement Among Republicans To Move Forward On Spending Deal; We Will Not Have A Government Shutdown

BlackBerry Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) stock surged upwards on Friday. The company reported <a target="_blank" href="https://www.benzinga.com/news/earnings/24/12/42606549/blackberry-beats-q3-earnings-estimates-but-soft-guidance-keeps-shares-in-check" rel="noreferrer noopener">third-quarter results</a> after the market closed on Thursday.
BlackBerry reported quarterly revenue of $143.00 million, missing the analyst consensus estimate of $161.49 million. The adjusted EPS was $0.02, beating analyst&nbsp;estimates.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/12/42529245/trump-and-netflix-boss-sarandos-set-for-high-stakes-mar-a-lago-meeting" rel="noreferrer noopener">Trump and Netflix Boss Sarandos Set for High-Stakes Mar-a-Lago Meeting</a>
BlackBerry expects fourth-quarter revenue of $126.00 million &#8211; $135.00 million, versus estimates of $150.08 million. It expects adjusted EPS of $(0.01) &#8211; $0.01. Analysts rerated the stock after the quarterly print.
RBC Capital analyst Paul Treiber reiterated BlackBerry with a Sector Perform and a <a target="_blank" href="https://www.benzinga.com/quote/BB/analyst-ratings" rel="noreferrer noopener">$3.25&nbsp;price target</a>.
BlackBerry&#8217;s third quarter marks its first quarter of financials without Cylance. The quarter exceeded Treiber&#8217;s estimates, though fourth-quarter guidance was short of his expectations.
Excluding Cylance (discontinued operations), third-quarter revenue was $143 million (-7% year-on-year), above Treiber&#8217;s estimated $128 million. All three revenue lines exceeded the analyst&#8217;s expectations: IoT ($62 million versus RBC and consensus at $58 million and $59 million), Secure Communications ($74 million versus RBC at $66 million), and Licensing ($7 million versus RBC and consensus at $4 million). Due to higher revenue, adjusted EBITDA was $35 million, above RBC at $13 million.
The fourth-quarter revenue guidance short of RBC. It calls for $126 million &#8211; $135 million in revenue, below RBC&#8217;s estimate of $138 million. The shortfall stems from Secure Communications ($62 million &#8211; $66 million versus RBC at $71 million). IoT guidance for $60 million &#8211; $65 million bracketed RBC estimate ($64 million). The mid-point of adjusted EBITDA guidance for $10 million &#8211; $20 million missed the RBC estimate of $19 million.
BlackBerry is now profitable and operating cash flow positive. However, Treiber noted that the valuation will likely remain discounted below that of peers pending improved IoT growth (fourth-quarter guidance calls for IoT revenue to be down 5% year-on-year at the mid-point).
BlackBerry is trading at a discounted valuation of 3.0 times NTM Enterprise Value/Sales.
Treiber noted that BlackBerry&#8217;s valuation will likely remain discounted, pending strengthening IoT growth and realizing improved profitability. The price target includes the $120 million cash proceeds from the sale of Cylance and values Secure Communications at 6.0 times calendar 2025 Enterprise Value/EBITDA (unchanged) and the IoT business at 6.1 times calendar 2025 Enterprise Value/ Sales (unchanged).
Price Action: BB stock is up 23.5% at $3.679 at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42536593/verizon-teams-up-with-nvidia-to-power-ai-apps-over-private-5g-networks" target="_blank" rel="noreferrer noopener">Verizon Teams Up With Nvidia To Power AI Apps Over Private 5G Networks</a></li>
</ul>
Image via Shutterstock.

Price Target

Reiteration

BlackBerry Growth Hinge On IoT, Secure Communications Despite Valuation Concerns: Analyst

Oppenheimer initiated coverage on Rhythm Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), a developer of treatment for rare obesity disorders.
The pharmaceutical industry&#8217;s focus on weight management is drawing strong investor interest, with Rhythm Pharmaceuticals standing out for targeting rare obesity disorders that standard treatments often fail to address.
The company is steadily growing its business through the global rollout of Imcivree, a drug designed for several<a href="https://www.benzinga.com/pressreleases/24/12/g42284805/rhythm-pharmaceuticals-announces-imcivree-setmelanotide-receives-expanded-marketing-authorization-" target="_blank" rel="noreferrer noopener"> genetic obesity conditions</a>.
Also Read: <a href="https://www.benzinga.com//node/42613036">Novo Nordisk&#8217;s Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges</a>
Revenue from global sales of IMCIVREE was $33.3 million for the third quarter of 2024, an increase of 14% on a sequential basis, primarily driven by sales for BBS.
In the third quarter of 2024, revenue of $23.3 million, or 70% of product revenue, was <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41757397/rhythm-pharmaceuticals-reports-third-quarter-2024-financial-results-and-business-update" rel="noreferrer noopener">generated in the U.S.</a>
Oppenheimer is optimistic about its progress in treating hypothalamic obesity, an acquired condition with high development potential, as Phase 3 trial results are expected in the first half of 2025.
Oppenheimer initiated coverage on Rhythm Pharmaceuticals with an Outperform rating and a <a target="_blank" href="https://www.benzinga.com/quote/RYTM/analyst-ratings" rel="noreferrer noopener">price target of $76</a>.
Rhythm&#8217;s expertise in MC4 biology positions it for long-term success as Imcivree&#8217;s approved uses expand, new pipeline drugs with improved efficacy and convenience advance, and the company enhances its efforts to identify patients with genetic obesity.
The analyst anticipates significant growth opportunities in 2025 and beyond as Rhythm taps into a multi-billion-dollar total addressable market.
The analyst highlights that severe obesity caused by MC4R pathway defects doesn&#8217;t respond well to popular GLP-1 drugs like Novo Nordisk A/S&#8217;&nbsp;&nbsp;Wegovy or Eli Lilly And Co&#8217;s Zepbound, noting the experts and studies.
The MC4R drug market has little competition. Palatin Technologies Inc. markets Vyleesi (bremelanotide) for sexual disorders and is testing it with Zepbound for general obesity, with results expected in early 2025. Palatin is also developing oral MC4R drugs.
Price Action: RYTM stock is up 1.71% at $56.43 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42623020/why-innovative-industrial-stock-is-falling-over-20-today" target="_blank" rel="noreferrer noopener">Innovative Industrial Properties Hit By Cannabis Company PharmaCann&#8217;s Rent Default, Stock Plunges</a></li>
</ul>
Photo via Shutterstock.

Initiation

RYTM

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

LTRY

Lottery.Com shares are trading higher after the company announced it received a Nasdaq compliance determination letter.

ENVX

Enovix shares are trading higher after the company announced it shipped its first EX-2M samples to customers manufactured in its Malaysian Fab 2 plant.

Comments

RUFFER INVST PART RED PRE by Ruffer Investment Company Ltd.

News

Latest news for RUFFER INVST PART RED PRE by Ruffer Investment Company Ltd. (OTC:RUFIF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga